2,3,4,6-Tetra-O-acetyl-D-galactopyranose - CAS 47339-09-3
Category:
Carbohydrates
Product Name:
2,3,4,6-Tetra-O-acetyl-D-galactopyranose
CAS Number:
47339-09-3
Molecular Weight:
348.3
Molecular Formula:
C14H20O10
COA:
Inquire
MSDS:
Inquire
Structure:
Monosaccharides
Chemical Structure
CAS 47339-09-3 2,3,4,6-Tetra-O-acetyl-D-galactopyranose

Related Monosaccharides Products


Reference Reading


1.Glycol chitosan/Nanohydroxyapatite Biocomposites for Potential Bone Tissue Engineering and Regenerative Medicine.
Dumont VC1, Mansur HS2, Mansur AA1, Carvalho SM1, Capanema NS1, Barrioni BR3. Int J Biol Macromol. 2016 Apr 13. pii: S0141-8130(16)30338-5. doi: 10.1016/j.ijbiomac.2016.04.030. [Epub ahead of print]
In the last few decades, research on biocomposite nanomaterials has grown exponentially due to the global demand for novel solutions in bone tissue engineering and repair. In the present study, it is reported the design and synthesis of biocomposites based on glycol chitosan (GLY-CHI) matrices incorporated with nano-hydroxyapatite particles (nHA) produced via an eco-friendly chemical colloidal process in water media followed by solvent casting and evaporation methods at room temperature. The structure, morphology, and crystallinity of the components and biocomposites were extensively characterized by light microscopy (LM), scanning electron microscopy (SEM), transmission electron microscopy (TEM), energy-dispersive X-ray spectroscopy (EDX), wavelength dispersive X-ray fluorescence spectroscopy (WD-XRF), X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), and X-ray micro-computed tomography analysis (μCT). Furthermore, cytotoxicity and cell viability tests were performed on three cell lines using a 3-(4,5-dimethylthiazol-2yl) 2,5-diphenyl tetrazolium bromide (MTT) assay, an alkaline phosphatase (ALP) activity test, and LIVE/DEAD® assays.
2.Risk factors for current and future unmet supportive care needs of people with pancreatic cancer. A longitudinal study.
Beesley VL1, Wockner LF2, O'Rourke P2, Janda M3, Goldstein D4,5, Gooden H6, Merrett ND7,8, O'Connell DL9, Rowlands IJ10, Wyld DK11,12, Neale RE2. Support Care Cancer. 2016 Apr 16. [Epub ahead of print]
PURPOSE: This study aims to determine if the supportive care needs of people with pancreatic cancer change over time and identify the factors associated with current and future unmet needs.
3.Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohort.
Rodger MA1, Scarvelis D2, Kahn SR3, Wells PS2, Anderson DA4, Chagnon I5, Le Gal G2, Gandara E2, Solymoss S6, Sabri E2, Kovacs MJ7. Thromb Res. 2016 Mar 29. pii: S0049-3848(16)30087-1. doi: 10.1016/j.thromres.2016.03.028. [Epub ahead of print]
BACKGROUND: Choosing short-term (3-6 months) or indefinite anticoagulation after a first unprovoked venous thromboembolic event (VTE) is a common and difficult clinical decision. The long-term absolute risk of recurrent VTE after a first unprovoked VTE, in all patients and sub-groups, is not well established, hindering decision making.
4.Metastasis to the lymph nodes along the proper hepatic artery from adenocarcinoma of the stomach.
Kumagai K1, Hiki N2, Nunobe S1, Irino T1, Ida S1, Ohashi M1, Yamaguchi T1, Sano T1. Langenbecks Arch Surg. 2016 Apr 16. [Epub ahead of print]
PURPOSE: The study sought the significance of resecting lymph nodes along the proper hepatic artery (station 12a) in gastric cancer surgery and the possibility of predicting station 12a involvement from clinicopathological factors or metastatic status in other regional lymph nodes of the stomach.